HC Wainwright & Co. Maintains Buy on Aurinia Pharmaceuticals, Raises Price Target to $15
Portfolio Pulse from Benzinga Newsdesk
HC Wainwright & Co. analyst Ed Arce maintains a 'Buy' rating on Aurinia Pharmaceuticals (NASDAQ:AUPH) and raises the price target from $14 to $15.
August 07, 2023 | 4:02 pm
News sentiment analysis
Sort by:
Ascending
POSITIVE IMPACT
Aurinia Pharmaceuticals' price target has been raised from $14 to $15 by HC Wainwright & Co. The firm maintains a 'Buy' rating on the stock.
The raised price target and maintained 'Buy' rating by HC Wainwright & Co. indicates a positive outlook for Aurinia Pharmaceuticals. This could potentially lead to an increase in the stock's price in the short term.
CONFIDENCE 90
IMPORTANCE 80
RELEVANCE 100